Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
McKesson
AstraZeneca
Merck
Harvard Business School

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FETZIMA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Fetzima

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02265367 Novel Medication as a Potential Smoking Cessation Aid Recruiting University of Minnesota - Clinical and Translational Science Institute N/A 2015-01-01 The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
NCT02288325 A Multicenter, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder Active, not recruiting Forest Laboratories Phase 4 2014-11-01 This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse (MDD).
NCT02431806 Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder Recruiting Forest Laboratories Phase 3 2015-06-01 The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.
NCT02466958 Trial of Levomilnacipran in Geriatric Depression Not yet recruiting University of California, Los Angeles Phase 3 2016-06-01 The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults.
NCT02720198 Levomilnacipran ER vs. Adjunctive Quetiapine ER for Adults With Inadequate Relief With SSRIs in MDD Not yet recruiting Forest Laboratories Phase 3 2016-03-01 This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine ER) to your existing treatment with people diagnosed with depression (major depression disorder). The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch.
NCT02720198 Levomilnacipran ER vs. Adjunctive Quetiapine ER for Adults With Inadequate Relief With SSRIs in MDD Not yet recruiting Institute for Advanced Medical Research, Alpharetta, GA Phase 3 2016-03-01 This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine ER) to your existing treatment with people diagnosed with depression (major depression disorder). The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fetzima

Condition Name

Condition Name for Fetzima
Intervention Trials
Major Depressive Disorder 2
Major Depressive Disorder (MDD) 1
Depressive Disorder, Major 1
Tobacco Use Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Fetzima
Intervention Trials
Depression 4
Depressive Disorder, Major 4
Depressive Disorder 4
Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Fetzima

Trials by Country

Trials by Country for Fetzima
Location Trials
United States 45
Canada 1
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Fetzima
Location Trials
Georgia 3
California 3
Oregon 2
New York 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Fetzima

Clinical Trial Phase

Clinical Trial Phase for Fetzima
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Fetzima
Clinical Trial Phase Trials
Recruiting 3
Not yet recruiting 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Fetzima

Sponsor Name

Sponsor Name for Fetzima
Sponsor Trials
Forest Laboratories 3
University of Minnesota - Clinical and Translational Science Institute 1
University of Ottawa 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Fetzima
Sponsor Trials
Other 5
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Harvard Business School
McKesson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.